Methods for the treatment of hepatitis B and hepatitis D infections
OwnerMichel Bazinet, Andrew Vaillantinventors
Life of this patent
Estimating the term…
Abstract
It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.
Claims9
A method for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, the method comprising administering to a patient in need of such treatment an antisense oligonucleotide that targets mRNA of the HBV genome encoding the hepatitis B surface antigen (HBsAg) and catalyzes degradation of that mRNA, and at least one pharmaceutically acceptable agent selected from the group consisting of:
- thymosin α1;
- interferon β-1a;
- interferon β-1b;
- interferon γ-1b;
- interferon λ1;
- interferon λ2;
- interferon λ3;
- pegylated interferon λ1;
- pegylated interferon λ2;
- GS-9620 (4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one);
- dehydroepiandrosterone;
- androstenediol;
- and
- androstenetriol.
A method for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, the method comprising administering to a patient in need of such treatment an antisense chelate complex formulation comprising an antisense oligonucleotide catalyzing the degradation of a mRNA used to produce the hepatitis B surface antigen (HBsAg) protein and at least one pharmaceutically acceptable agent selected from the group consisting of:
- thymosin α1;
- interferon α-2a;
- interferon α-2b;
- interferon α-N3;
- interferon β-1a;
- interferon β-1b;
- interferon γ-1b;
- interferon λ1;
- interferon λ2;
- interferon λ3;
- pegylated interferon α-2a;
- pegylated interferon α-2b;
- pegylated interferon λ1;
- pegylated interferon λ2;
- GS-9620 (4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one);
- dehydroepiandrosterone;
- androstenediol;
- and
- androstenetriol.
A method for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, the method comprising administering to a patient in need of such treatment an antisense oligonucleotide that targets mRNA of the HBV genome encoding the hepatitis B surface antigen (HBsAg) and catalyzes degradation of that mRNA, and at least one pharmaceutically acceptable agent selected from the group consisting of:
- thymosin α1;
- interferon α-2a;
- interferon α-2b;
- interferon α-N3;
- interferon β-1a;
- interferon β-1b;
- interferon γ-1b;
- interferon λ1;
- interferon λ2;
- interferon λ3;
- pegylated interferon α-2a;
- pegylated interferon α-2b;
- pegylated interferon λ1;
- pegylated interferon λ2;
- GS-9620 (4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one);
- dehydroepiandrosterone;
- androstenediol;
- and
- androstenetriol, and
- at least one second pharmaceutically acceptable agent selected from the group consisting of:
- tenofovir disoproxil fumarate;
- entecavir;
- telbuvidine;
- adefovir dipivoxil;
- and
- lamivudine.
Dependencies are inferred from the claim text.